Engineered Trimeric CD70 Proteins and Uses Thereof, Fred Hutchinson Cancer Center, EP4041410A2

European Patent application EP4041410A2 filed by Fred Hutchinson Cancer Center for engineered trimeric CD70 proteins and uses thereof, published April 15, 2026. The application covers engineered trimeric CD70 proteins with therapeutic applications including anticancer uses, classified under IPC A61P 35/00 and C07K 16/40. The application designates 31 European Patent Convention contracting states for potential patent protection.

Anti-Sortilin Antibodies for Use in Therapy by Alector LLC

The European Patent Office published patent application EP3983441A1 for Alector LLC, covering anti-sortilin antibodies for therapeutic use in neurological conditions. The application was published April 15, 2026 under IPC classification C07K 16/28 (peptides, antibodies) with designations across 35 European states. Inventors include Robert Paul, Michael F. Ward, Hua Long, Shiao-Ping Lu, Omer Rizwan Siddiqui, Arnon Rosenthal, and Herve Rhinn.

University of California MOG Peptide Glioblastoma Patent Application

The Regents of the University of California published European patent application EP4054596A1 on April 15, 2026, covering the use of MOG peptide for priming glioblastoma treatment. The application names six inventors and includes ten IPC classifications spanning peptide sequences, cancer therapeutics, and cellular immunotherapies across 31 designated contracting states.

Legend Biotech Single Domain Antibodies CAR-T BCMA

EPO published patent application EP4077398A1 covering single domain antibodies and chimeric antigen receptors targeting BCMA, assigned to Legend Biotech Ireland Limited and Legend Biotech USA Inc. The invention relates to cancer treatment methods using BCMA-targeted CAR-T cells and single domain antibodies. Six inventors are listed: Fan Xiaohu, Zhuang Qiuchuan, Zhao Yuncheng, Yang Lei, Fang Xu, and Xu Changmeng.

GLP-2 Conjugate Pharmaceutical Composition for Metabolic Bone Diseases, Hanmi Pharm.

The European Patent Office published application EP4082561A1 for Hanmi Pharm. Co., Ltd. on April 15, 2026. The application covers a pharmaceutical composition comprising GLP-2 or a conjugate thereof for preventing or treating metabolic bone diseases, with inventors including CHOI Jae Hyuk, LEE Jin Bong, LEE Sang Hyun, LEE Sang Don, and KIM Min Young. The application spans 31 designated contracting states including major European economies.

Anti-HERV-W Envelope Protein Antibody for Psychotic Diseases, Geneuro SA

The European Patent Office published application EP4157871A1, filed by Geneuro SA and Fondamental, covering an anti-HERV-W envelope protein antibody for use in treating psychotic diseases. Inventors are Marion Leboyer and Hervé Perron. The application, classified under IPC C07K 16/28 (antibodies) and A61P 25/18 (CNS disorders/pscychotic diseases), designates all European Patent Convention member states. This is a routine patent application publication by the EPO Patent Bulletin.

EP4157861A1 - Anorexic Peptide Compositions and Uses by CSIC

The European Patent Office published application EP4157861A1 filed by Consejo Superior de Investigaciones Científicas (CSIC) for peptide compositions capable of inducing anorexic hormones, along with methods of use and pharmaceutical preparations. The application, covering IPC classifications including C07K 14/47, C07K 14/77, A61K 38/00, and A61P 3/04, names five inventors: Recio Sánchez, Santos Hernández, Miralles Buraglia, Hernández Ledesma, and Amigo Garrido. The application designates 33 European states including DE, FR, GB, IT, NL, ES, and SE.

EP4157335A2 Peptide Cocktail by Hubro Therapeutics AS

The European Patent Office published application EP4157335A2 filed by Hubro Therapeutics AS (Norway) for a peptide cocktail composition, with inventors Henrik Eriksen and Jon Amund Eriksen. The application was published April 15, 2026, under IPC classifications A61K 39/00 (immunological preparations), A61P 35/00 (antineoplastic agents), and C07K 14/00 (peptides), covering designated contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Takeda Vaccines Inc - EP4153222A1 - Zika Virus Antibody Detection

Takeda Vaccines, Inc. has obtained European Patent Application EP4153222A1 for a method of detecting Zika virus-specific antibodies. The application names inventors Perez-Guzman, Nascimento, Dean, and Braun and covers IPC classifications spanning immunological preparations, peptides, and nucleic acid detection methods. The patent is designated across 34 European states including Germany, France, the United Kingdom, Italy, and Spain.

Former WRRS CEO Michael Sacco Abused Public Funds

The Massachusetts Office of the Inspector General released an investigation finding that former Worcester Regional Retirement System (WRRS) CEO Michael Sacco expanded his private law practice while being paid a full-time public salary. The OIG found that Sacco only worked 20 to 30 hours per week for WRRS while attending 350 outside board meetings, court hearings, and other engagements on behalf of private clients during WRRS business hours, without using leave time. The OIG made 28 recommendations, including that the WRRS Board pursue recovery of funds for allegedly unused vacation time and that the Legislature prevent passage of House Bill 2931 which would exempt Sacco from post-retiree earnings caps.

Namibia Q4 2025 Economic Report: 0.5% GDP Contraction, 3.4% Inflation, N$172.7B Debt

The Bank of Namibia released its Q4 2025 quarterly economic report showing the domestic economy contracted by 0.5 percent year-on-year, driven by declines in diamond production and weaker manufacturing output, with nominal GDP estimated at N$72.0 billion. Headline inflation remained at 3.4 percent quarter-on-quarter while Central Government debt stock reached N$172.7 billion at the end of December 2025, representing 64.0 percent of GDP and remaining above the SADC benchmark of 60 percent. The current account deficit narrowed to N$10.1 billion from N$12.3 billion in the same quarter of 2024.

Namibia Economy Projected to Grow 2.6% in 2026

The Bank of Namibia released its March 2026 Economic Outlook update, projecting Namibia's domestic economy to grow 2.6 percent in 2026 and 2.9 percent in 2027, compared to an estimated 1.7 percent growth in 2025. The 2026 and 2027 projections reflect downward revisions of 1.2 percentage points and 1.4 percentage points respectively, from the December 2025 Economic Outlook update, driven primarily by weaker performance in primary industries including metal ores and diamond mining. Growth is expected to be supported by expansion in construction, electricity and water, wholesale and retail trade, financial services, and public administration and defence, as well as uranium mining operations.

Insurance Commissioner Amanda Crawford to Host Public Event April 10

The Texas Department of Insurance will host a Speak Up, Texas! public event in Nacogdoches on Friday, April 10, 2026, from 2:30 to 4 p.m. at The Fredonia Hotel. Insurance Commissioner Amanda Crawford will discuss the home and auto insurance market, tips for shopping for insurance, and how TDI can assist Texans. Texans unable to attend in person can submit ideas online at www.tdi.texas.gov/speakuptexas.

Commissioner Crawford Hosts Speak Up Texas Event San Antonio April 17

TDI Commissioner Amanda Crawford will host a Speak Up, Texas! community event on Friday, April 17, 2026, from 5 to 6:30 p.m. at UT San Antonio's Downtown Campus in the Durango Building's Riverwalk Room B (501 W. Cesar E. Chavez Blvd.). The event invites Texans to share ideas on strengthening and improving the home and auto insurance market, learn tips for shopping for insurance, and understand how TDI can assist Texas consumers. Texans unable to attend in person can submit feedback online at tdi.texas.gov/speakuptexas.

Leonardo Villar Presents BanRep Board Report to Senate

Leonardo Villar, Gerente General del Banco de la República, presentó el Informe de la Junta Directiva del Banco al Congreso de la República ante la Comisión Tercera del Senado el miércoles 22 de abril de 2026. La presentación se realizó como parte de las funciones de rendición de cuentas del banco central ante el legislativo colombiano. El documento incluye la intervención de Villar Gómez ante los senadores de la comisión.

Bank Co-Directors Discuss Monetary Policy Book at Bogotá Book Fair 2026

Banco de la República de Colombia announces its participation in the 2026 International Book Fair of Bogotá (FILBo), where co-directors Bibiana Taboada and Mauricio Villamizar will host a public conversation on April 23 at 2:00 p.m. in Auditorium Pabellón Colombia about their book 'Mitos y realidades de la política monetaria'. The event is open to the general public and aims to promote informed debate about monetary policy, covering topics such as inflation, interest rates, labor markets, production, exchange rates, climate change, inequality, and public policy.

Alerta: Usan IA para Suplantar al Gerente General del BanRep en Videos Falsos

El Banco de la República emitió una alerta pública el 18 de abril de 2026 desmentiendo un video falso publicado en redes sociales que utiliza inteligencia artificial para manipular la imagen del Gerente General, simulando una entrevista en Noticias RCN. La entidad aclaró que los contenidos son fraudulentos y no corresponden a comunicaciones oficiales. Como medida de precaución, el Banco recomienda a la ciudadanía verificar siempre la fuente de la información, no diligenciar datos personales en enlaces no confiables y consultar únicamente los canales oficiales del Banco para información verificada.

House Passes H. Res. 1189, 211-206

The House passed H. Res. 1189 by a vote of 211 to 206 on April 22, 2026. The procedural resolution provides for floor consideration of H.R. 4690, H. Res. 1182, H.R. 1897, and H.R. 5587, governing debate time allocation and permissible amendments for each measure. The vote split sharply along party lines with all 205 voting Democrats opposed, 210 of 211 Republicans in favor, one Independent voting yes, and 14 members not voting.

H. Res. 1189 Previous Question Vote Passes 180-179

The House voted 180-179 on April 22, 2026 to order the Previous Question on H. Res. 1189, a rule providing for floor consideration of H.R. 4690, H. Res. 1182, H.R. 1897, and H.R. 5587. The margin was razor-thin with 72 members not voting. Republicans voted uniformly in favor (179-0) while all 179 present Democrats voted against, with one Independent joining Republicans.

Rural Support Resolution Passes 220-196

H. Res. 1182, expressing support for rural communities as environmental stewards, energy resource suppliers, food production providers, and drivers of economic stability, passed the House on April 22, 2026 by a vote of 220-196. The resolution passed largely along party lines with 212 Republicans and 7 Democrats voting in favor, while 196 Democrats voted against. As a simple House resolution, this measure carries no binding legal effect and serves as an expression of congressional sentiment.

FIRE Act Motion to Recommit Fails 206-214

The U.S. House of Representatives voted on a Motion to Recommit regarding the FIRE Act on April 22, 2026. The motion failed with 206 votes in favor and 214 votes against, with 10 members not voting and 0 present. Republicans voted uniformly against the motion (213 nay, 4 not voting) while all Democrats voting (206) supported it.

H.R. 4690 Reliable Federal Infrastructure Act Passed 215-202

The House passed H.R. 4690, the Reliable Federal Infrastructure Act, by a vote of 215-202 on April 22, 2026 during the 119th Congress, 2nd Session. The vote split largely along party lines with 209 Republicans and 6 out of 218 Democrats supporting passage, while 1 Republican voted against. The bill now proceeds to the Senate for consideration.

H.R. 4690 Motion to Recommit Fails 203-214

The House of Representatives voted on H.R. 4690 (Reliable Federal Infrastructure Act), with a motion to recommit failing 203-214. All Republicans voted against recommitment while all Democrats plus one Independent voted in favor. The vote took place on April 22, 2026 during the 119th Congress, 2nd Session.

H.R. 6387 FIRE Act Passes House 220-198

The House of Representatives passed H.R. 6387, the FIRE Act, by a vote of 220-198 on April 22, 2026. Republicans supported the bill 211-1 while Democrats opposed it 197-8 with 12 members not voting. The bill now proceeds to the Senate for consideration before it can be presented to the President for signature.

RBZ Graduate Trainee Programme 2026-2028 Law Media Studies

The Reserve Bank of Zimbabwe (RBZ) has announced a 2-year Graduate Trainee Programme for the 2026-2028 cohort, inviting applications from graduates holding a minimum First Class (1) Degree in Law or Media Studies. The programme offers structured training in central banking operations including monetary policy, financial markets, banking supervision, and economic research. Interested candidates should submit applications with CV, certified copies of educational certificates, ID and transcript to gtcareers@rbz.co.zw.

ZiG Stability, 4.1% Inflation, US$1.4B Reserves, New Banknotes

The Reserve Bank of Zimbabwe published its Q1 2026 quarterly snapshot reporting macroeconomic and financial sector developments. Key indicators include single-digit annual ZiG inflation of 4.1% achieved in January 2026 for the first time in over three decades, sustained month-on-month inflation averaging 0.2% through March 2026, and foreign currency reserves standing at US$1.4 billion representing approximately 1.5 months of import cover as of 31 March 2026. Foreign currency receipts totaled US$4.97 billion in the first three months of 2026, a 54.1% increase compared to US$3.22 billion in the same period of 2025, while the interbank exchange rate remained stable at approximately ZiG25 per US dollar. The Reserve Bank also launched the upgraded BiG 5 ZiG Banknote Series alongside a nationwide education and awareness campaign.

Diogo Thomson Named Interim CADE President

Conselheiro Diogo Thomson de Andrade assumed interim presidency of Brazil's Conselho Administrativo de Defesa Econômica (CADE) on April 12, 2026, succeeding Gustavo Augusto whose term ended. Thomson has been with CADE since 2007, serving as a prosecutor, administrative instructor, and deputy superintendent for over a decade before joining the Tribunal as a counselor in 2023. His appointment crowns a near-two-decade career traversing every level of Brazil's competition authority.

CADE Publishes 2025 Integrated Management Report

CADE Brazil published its 2025 Integrated Management Report on April 15, 2026, consolidating institutional results, governance practices, and public resource management under four structural axes: organizational overview, governance and strategy, risk management, and budget execution. The report reflects the agency's work in promoting fair and efficient competition aligned with constitutional principles.

Three Cases on CADE Agenda Thursday Diogo Thomson

CADE Brazil published the agenda for its 264th Ordinary Judgment Session in the Diário Oficial da União on April 16, 2026. The session is scheduled for Thursday April 23 at 10h, broadcast live on YouTube, and will be the first presided over by interim president Diogo Thomson who took office on April 12. Three cases are listed: Administrative Inquiry 08700.003498/2019-03 against Google Inc. and Google Brasil Internet Ltda. (relator Gustavo Augusto, vote-vista Camila Cabral); Administrative Proceeding 08700.002545/2023-70 from the Paraná state prosecutor against six respondents including Augustinho Stang and several fuel and commerce companies (relator José Levi); and Administrative Proceeding 08700.002556/2026-01 for incidental procedural sanctions against WhatsApp LLC and Facebook Serviços Online do Brasil (relator Carlos Jacques).

Illinois Green Film Tax Credit, 5% Additional Uplift

Illinois has launched a first-in-the-nation Green Film Tax Credit program offering an additional 5% tax credit uplift for film and television productions that achieve "certified green production" status through the Illinois Film Office, which uses a comprehensive scoring system to measure environmental impact across all phases of production. The announcement coincides with Illinois' film production expenditures reaching a record $703 million in 2025, supporting approximately 18,000 industry hires. The program is designed to incentivize sustainable practices including waste minimization, energy reduction, efficient transportation, sustainable materials, and responsible food practices on set.

11 Therapy Canine Teams Graduate in Illinois Crisis Response Program

The Illinois Law Enforcement Training and Standards Board (ILETSB), in partnership with the Cook County Sheriff's Office (CCSO), graduated the inaugural cohort of the nation's first Crisis Response Therapy Canine Certification Program on April 22, 2026. The 11 certified therapy canine teams representing seven Illinois agencies completed rigorous training in crisis intervention, behavioral health awareness, and canine-handler coordination. The program establishes standardized training guidelines for therapy canines working alongside law enforcement in mental health calls, community engagement, and post-trauma response situations.

Illinois State Fair 2026, 100 Days Celebration, May 5th

The Illinois Department of Agriculture announced the 2026 Illinois State Fair "100 Days Out" Celebration, scheduled for May 5, 2026 from 10:30 a.m. to 2:30 p.m. at the Reisch Pavilion on the Illinois State Fairgrounds. The free event will feature food vendors including Mickey's Massive Burritos, On Point Concessions, Taft's Mr. Ribeye, Vose's Korndog, and Scoop Du Jour, along with prize package giveaways. The 2026 Illinois State Fair itself will run from August 13-23.

Toyota ShareLunker Program 2026 Season Delivers 18 Legacy Class Fish From 10 Texas Lakes

The Texas Parks and Wildlife Department announced results of the 2026 Toyota ShareLunker collection season, celebrating the program's 40th anniversary with 18 Legacy Class ShareLunkers submitted from 10 different public lakes across Texas. Two waterbodies (Hords Creek Reservoir and Ellison Creek Reservoir) recorded their first Legacy Class fish, while four lakes set new waterbody records. O.H. Ivie retained bragging rights for most entries for the sixth consecutive season with five Legacy Class ShareLunkers, bringing its total to 63 since 2020. The program focuses on habitat improvement, stocking programs, and genetic research for largemouth bass conservation.

Governor Spanberger Statement on Redistricting Referendum Outcome

Governor Abigail Spanberger released a statement on April 21, 2026, following Virginia voters' approval of a temporary redistricting measure. The approved measure was designed to push back against claims of entitlement to additional Republican seats in Congress. The statement acknowledges voter rejection of similar demands in other states and reaffirms commitment to Virginia's bipartisan redistricting commission resuming work after the 2030 census.

Governor Spanberger Signs Momnibus Bills to Improve Maternal Healthcare, Support Virginia Mothers

Governor Abigail Spanberger signed the Virginia Momnibus legislative package on April 22, 2026, enacting four bipartisan bills to improve maternal healthcare coverage. The package includes HB1400 expanding maternal mental healthcare screenings, HB1403 directing the Department of Health to develop a Severe Maternal Morbidity reporting system, HB425 authorizing Medicaid reimbursements for remote monitoring of high-risk pregnant women, and HB1353 directing the Commissioner of Health to assess a statewide maternal health safety initiative. The legislation targets Virginia's high maternal mortality rate, particularly for Black women who face elevated risks compared to other demographics.

Additional Practical Exam Testing Date April 29, Montgomery

PSI, the Alabama Board of Cosmetology and Barbering testing partner, has added an additional practical exam testing date on April 29 in Montgomery, Alabama. This supplementary testing event precedes the launch of updated cosmetology and barbering examinations scheduled for May 1, 2026. Test takers are instructed to log into their PSI online portal, select Montgomery Practical as the site location, and schedule their exam before all available spots are filled.

XR Resilience Training RCT for 232 Hospital Nurses

A new ClinicalTrials.gov registry entry (NCT07544498) describes a pragmatic randomized controlled trial evaluating an extended reality (XR) based resilience training program for approximately 232 hospital nurses across several European countries. The trial compares eight immersive XR training sessions delivered via head-mounted display over ten weeks against a waitlist control, measuring perceived stress as the primary outcome.

Combined Ovarian Tissue and Oocyte Cryopreservation for Fertility

NIH ClinicalTrials.gov registered observational study NCT07546123 will compare combined ovarian tissue cryopreservation with oocyte cryopreservation against oocyte cryopreservation alone in oncological patients undergoing gonadotoxic treatments. The study will collect data from two groups of patients assigned based on their planned gonadotoxic therapy and available time before treatment initiation. The primary endpoints are the number of oocytes retrieved per ovarian stimulation cycle and the oocyte retrieval rate between the two groups.

RAB001 Phase 1, Osteonecrosis, 16 Healthy Subjects

A Phase 1 clinical trial for RAB001 (LLP2A-Ale) has been registered on ClinicalTrials.gov (NCT07545018) examining safety, tolerability, and pharmacokinetics in 16 healthy subjects across two dose groups (400 μg/kg and 750 μg/kg) for the treatment of Osteonecrosis of the Femoral Head. The single-center, randomized, double-blind, placebo-controlled dose escalation study includes both single-dose and multiple-dose phases with injections administered once every 2 weeks.

Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus

A new observational study (NCT07545408) registered on ClinicalTrials.gov will evaluate subclinical atherosclerosis in children and adolescents with juvenile systemic lupus erythematosus (SLE) by measuring carotid intima-media thickness (CIMT), and will assess associations with both traditional cardiovascular risk factors (dyslipidemia, hypertension, obesity) and non-traditional disease-related risk factors (disease activity, lupus nephritis, corticosteroid dose, disease duration). The study is listed as observational with an anticipated end date.

Ultrasound-guided Pharmacopuncture Spinal Disease Registry Trial, 600 Patients, 6 Sites

The NIH ClinicalTrials.gov registry has posted an observational multi-center registry study (NCT07543692) evaluating the safety and effectiveness of ultrasound-guided pharmacopuncture for patients with spinal diseases. The study will enroll 600 patients aged 19 to under 70 across six Korean medicine hospitals, requiring a pain Numeric Rating Scale score of 5 or higher for eligibility. Participants already planned to receive ultrasound-guided pharmacopuncture as part of routine clinical care will be observed; the primary outcome is change in most dominant spinal pain intensity from baseline to 4 weeks. Secondary outcomes include functional disability (NDI/ODI), quality of life (EQ-5D-5L), and patient satisfaction, with safety monitored via adverse event assessment at every visit. This is a non-interventional registry study with no new compliance obligations for external parties.

Health and Wellness Coaching for Thyroid Cancer Survivors, NCT07545837

Clinical trial NCT07545837 registered on ClinicalTrials.gov evaluates a patient-centered health and wellness coaching (HWC) intervention targeting adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid cancer. The trial will enroll thyroid cancer survivors who have undergone surgery, radioactive iodine, and/or lifelong levothyroxine therapy with regular thyroid stimulating hormone monitoring. Interventions include counseling, interviews, and questionnaire administration to assess HWC's impact on self-care, health-related goal-setting, and survivorship care outcomes.

Phase 1 CAR T Cell Trial for Recurrent High-Grade Gliomas

This Phase 1 clinical trial registered on ClinicalTrials.gov (NCT07544992) will evaluate the safety and optimal dosing of EGFR/IL13Rα2 pool-CAR T cells administered locoregionally (via intracranial catheter) in patients with recurrent or progressive high-grade gliomas, including recurrent astrocytoma (IDH-mutant, grade 4) and recurrent glioblastoma (IDH-wildtype). The trial involves leukapheresis to collect patient T cells, genetic engineering to express chimeric antigen receptors targeting EGFR and IL13Rα2 proteins on tumor cells, and subsequent infusion of the modified cells.

Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes

This clinical trial registration (NCT07546409) describes a randomized study assessing whether older adults with prediabetes show differences in brain glucose uptake and cognitive processing speed compared to age-matched controls with normal glucose levels. The trial will test a single dose of an exogenous ketone monoester supplement (DeltaG) against placebo in approximately 100 participants, measuring outcomes via 18F-FDG-PET/MRI brain imaging and cognitive testing. Estimated study completion date is April 22, 2026.

Observational Study Biomarkers Osteoarthritis China

ClinicalTrials.gov registered an observational study (NCT07544823) titled 'Screening for Biomarkers of Osteoarthritis' conducted in China, posted April 22, 2026. The study intends to collect blood samples from osteoarthritis patients and suspected patients at a tertiary hospital orthopedic outpatient department, using diagnostic and differential diagnostic tests to verify candidate biomarkers. Researchers aim to screen biomarkers with favorable validity and reliability to support early prevention, early diagnosis, and individualized intervention for osteoarthritis.

Phase 1 ISAR InflEx Trial: Exercise Inflammation CVD

A new Phase 1 clinical trial called ISAR InflEx (Inflammation and Exercise) has been registered on ClinicalTrials.gov under identifier NCT07543666, with an estimated start date of April 22, 2026. The trial will investigate how three distinct exercise modalities—moderate-intensity, vigorous-intensity, and short-duration maximal exercise—affect systemic inflammation and immune function in sedentary adults with obesity, a population at elevated risk for cardiovascular disease. The study aims to characterize exercise as a potential anti-inflammatory intervention for CVD prevention, enrolling participants who meet specific inclusion criteria related to sedentary behavior and weight status.

Celgene/Zoetis Helminthic Drug Patent Published by EPO

The European Patent Office published patent application EP4232449A1 for Celgene Corporation and Zoetis LLC, covering heterocyclic compounds and their use for treating helminthic infections and diseases, published April 15, 2026. The compounds carry multiple IPC classifications including C07D 417/14, C07D 413/14, C07D 401/14, C07D 471/04, C07D 491/048, and are designated across 31 European states including DE, FR, GB, IT, NL, ES, PL, SE. The publication establishes priority rights and enables public inspection of the specific heterocyclic compound compositions and therapeutic uses disclosed in the application.

EP4144736A1 - Azabenzimidazoles AMPA Receptor Modulators, Janssen, Apr 15, 2026

The EPO published patent application EP4144736A1 titled 'Azabenzimidazoles and Their Use as AMPA Receptor Modulators' on April 15, 2026, covering novel heterocyclic compounds as AMPA receptor modulators for neurological and pain conditions. The application was filed by Janssen Pharmaceutica NV with 13 named inventors. The patent designates 37 EPO contracting states.

Roche EP4251614A1: N-Substituted Aniline Hepatitis B Treatment

The EPO has granted patent EP4251614A1 to F. Hoffmann-La Roche AG covering N-substituted 4-(5-phenyl-1,3,4-oxadiazol-2-yl)aniline compounds for the treatment and prophylaxis of hepatitis B virus infection. The patent, filed with four named inventors (LIN Xianfeng, YUN Hongying, ZHANG Bo, ZHENG Xiufang), carries IPC classifications spanning C07D chemical compounds and A61K/A61P pharmaceutical preparations. Designated states include all major European Patent Convention member states. This grant confers exclusive rights to Roche across EU member jurisdictions for the claimed HBV therapeutic applications.

Captor Therapeutics European Patent Application EP4347579A1 for MCL-1 Targeted Protein Degradation

Captor Therapeutics S.A. has obtained publication of European patent application EP4347579A1 covering bifunctional compounds designed to bind ubiquitin ligase and recruit the MCL-1 protein for degradation, with potential therapeutic application in oncology. The application was published on April 15, 2026 with claims spanning heterocyclic compound compositions under IPC classifications C07D 401/14, C07D 471/04, C07D 513/04, and related therapeutic uses under A61P 35/00 and A61K 31/4439. The designated states include all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).